Ask AI
ProCE Banner Activity

PARP Inhibitors for Prostate Cancer: Expert Answers to Your Questions

Clinical Thought

Daniel P. Petrylak, MD, answers healthcare professionals’ questions on leveraging PARP inhibitor–based therapies for prostate cancer, including gene differences in sensitivity to PARP inhibition, when to repeat somatic testing, and how to choose between approved PARP inhibitor combination regimens.

Released: April 09, 2024

Expiration: April 08, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA

Faculty Disclosure

Primary Author

Daniel P. Petrylak, MD

Professor of Medicine and Urology
Director, Genitourinary Oncology Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Infinity, Ipsen, Janssen, Lilly, Merck & Company, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi Aventis, Seattle Genetics, Urogen; researcher: Ada Cap, Agensys, Arvians, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Onocology, Daiichi Sankyo, Esiai, Endocyte, Ferring, Genentech, Gilead Sciences, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics.